Tivozanib Recommended for EU Approval for RCC

June 23, 2017 – The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization of tivozanib for adult patients with advanced renal cell carcinoma (RCC). The committee is an arm of the European Medicines Agency’s (EMA). Should the full committee accept the positive opinion, tivozanib would be approved for use in the 28 European Union member states plus Norway and … (leggi tutto)